

# CURRICULUM VITÆ

## Kozma, Bence PhD



### EXPERIENCE

In the biopharma industry since university graduation. Actively involved in the upstream PAT development of four different biosimilar monoclonal antibodies. Expert in Raman, (N)IR and Dielectric spectroscopy, solid knowledge of Multivariate Data Analysis techniques and bioprocess development.

Stayed in academia and transitioned from monoclonal antibodies to cell therapies. Currently involved in two research projects and building a laboratory for cell therapy process development work.

- |           |   |
|-----------|---|
| 2024–     | Project Assistant, PostDoc, Integrated Bioprocess Development, Technische Universität Wien, Austria<br>Involved in a variety of projects in the field of PAT for different bioprocesses and ATMPs                         |
| 2019–2023 | Project Assistant, PostDoc, Bioprocess Technology Research Group, Technische Universität Wien, Austria<br>Involved in a variety of projects in the field of PAT for different bioprocesses and ATMPs                      |
| 2018–2019 | R&D Engineer, Upstream dev., Biotechnology R&D, Gedeon Richter Plc., Hungary<br>PAT and data scientist  |
| 2015–2018 | PhD Student, Biotechnology R&D, Gedeon Richter Plc., Hungary<br>Conducting spectroscopic experiments related to my PhD work;<br>Involved in PAT development of cell cultivation projects                                  |
| 2013–2015 | Internship, Biotechnology R&D, Gedeon Richter Plc., Hungary<br>FT-NIR measurements and data analysis of CHO cell cultivations; Application of different analytical techniques to measure glucose in CHO cell cultivations |

### EDUCATION

- |           |  |
|-----------|--|
| 2015–2019 | Budapest University of Technology and Economics, George A. Olah Doctoral School of Chemistry and Chemical Technology, PhD<br>Research field: Application of Near infrared, Raman and dielectric spectroscopies to mammalian cell cultivation monitoring as Process Analytical tools. |
| 2013–2015 | Budapest University of Technology and Economics, MSc. in bioengineering, grade: excellent  |

### LANGUAGES

- Hungarian (native)
- English (fluent)
- German (elementary)
- French (elementary)

## PUBLICATIONS

García Aponte O.F., **Kozma B.**, Egger D., Kasper C., Herwig C. Kinetics of NK-92 growth and functionality in pseudo-static cultures (2023) *Biochemical Engineering Journal*, 196, DOI: 10.1016/j.bej.2023.108929

García Aponte O.F., Herwig C., **Kozma B.** Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy (2021) *Journal of Biological Engineering*, 15 (1) DOI: 10.1186/s13036-021-00264-7

Zalai D., Kopp J., **Kozma B.**, Kűchler M., Herwig C., Kager J. Microbial technologies for biotherapeutics production: Key tools for advanced biopharmaceutical process development and control (2020) *Drug Discovery Today: Technologies*, 38, pp. 9 – 24 DOI: 10.1016/j.ddtec.2021.04.001

**Kozma B.**, Salgó A., Gergely S. On-line glucose monitoring by near infrared spectroscopy during the scale up steps of mammalian cell cultivation process development (2019) *Bioprocess and Biosystems Engineering*, 42 (6), pp. 921 – 932 DOI: 10.1007/s00449-019-02091-z

**Kozma B.**, Salgó A., Gergely S. Comparison of multivariate data analysis techniques to improve glucose concentration prediction in mammalian cell cultivations by Raman spectroscopy (2018) *Journal of Pharmaceutical and Biomedical Analysis*, 158, pp. 269 – 279 DOI: 10.1016/j.jpba.2018.06.005

**Kozma B.**, Hirsch E., Gergely S., Párta L., Pataki H., Salgó A. On-line prediction of the glucose concentration of CHO cell cultivations by NIR and Raman spectroscopy: Comparative scalability test with a shake flask model system (2017) *Journal of Pharmaceutical and Biomedical Analysis*, 145, pp. 346 – 355 DOI: 10.1016/j.jpba.2017.06.070

**Kozma B.**, Párta L., Zalai D., Gergely S., Salgó A. A model system and chemometrics to develop near infrared spectroscopic monitoring for Chinese hamster ovary cell cultivations (2014) *Journal of Near Infrared Spectroscopy*, 22 (6), pp. 401 – 410 DOI: 10.1255/jnirs.1133

January 2024